Literature DB >> 33628244

Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis.

Lushi Yu1, Hongyun Gong1, Qian Li1, Honggang Ren1, Yi Wang1, Haihua He1, Tian Li2, Qibin Song1.   

Abstract

RESULTS: A total of 20031 ovarian cancer patients were included, with 291 (1.45%) patients who received radiotherapy. The median overall survival (OS) in patients who received radiotherapy was shorter than which in patients without radiotherapy (23 vs. 75 months, P < 0.001). The Elderly, nonepithelial pathology, advanced American Joint Committee on Cancer (AJCC) stage, elevated level of CA125, and receiving radiotherapy were risk predictors to survival in both multivariable analyses before and after PSM. Among 11872 patients with III/IV stage, the radiotherapy group also showed a significantly worse prognosis (median OS: 19 vs. 44 months in patients without radiotherapy, P < 0.001). Consistent results were observed in stratification analyses on pathology and stage among patients with III/IV stage.
CONCLUSIONS: For patients with ovarian cancer, radiotherapy was associated with a poor prognosis regardless of pathology or stage. Considering this is a retrospective study, future studies concerning radiotherapy combination with other new agents in ovarian cancer are needed.
Copyright © 2021 Lushi Yu et al.

Entities:  

Year:  2021        PMID: 33628244      PMCID: PMC7892241          DOI: 10.1155/2021/8849039

Source DB:  PubMed          Journal:  J Oncol        ISSN: 1687-8450            Impact factor:   4.375


  24 in total

1.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

2.  Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy.

Authors:  Anupama Chundury; Anthony Apicelli; Todd DeWees; Matthew Powell; David Mutch; Premal Thaker; Clifford Robinson; Perry W Grigsby; Julie K Schwarz
Journal:  Gynecol Oncol       Date:  2016-02-10       Impact factor: 5.482

3.  Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma.

Authors:  A W Fyles; A J Dembo; R S Bush; W Levin; L A Manchul; J F Pringle; G A Rawlings; J F Sturgeon; G M Thomas; J Simm
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

4.  Ovarian cancer statistics, 2018.

Authors:  Lindsey A Torre; Britton Trabert; Carol E DeSantis; Kimberly D Miller; Goli Samimi; Carolyn D Runowicz; Mia M Gaudet; Ahmedin Jemal; Rebecca L Siegel
Journal:  CA Cancer J Clin       Date:  2018-05-29       Impact factor: 508.702

5.  Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.

Authors:  Philipp Harter; Andreas du Bois; Maik Hahmann; Annette Hasenburg; Alexander Burges; Sibylle Loibl; Martina Gropp; Jens Huober; Daniel Fink; Willibald Schröder; Karsten Muenstedt; Barbara Schmalfeldt; Guenter Emons; Jacobus Pfisterer; Kerstin Wollschlaeger; Hans-Gerd Meerpohl; Georg-Peter Breitbach; Berno Tanner; Jalid Sehouli
Journal:  Ann Surg Oncol       Date:  2006-12       Impact factor: 5.344

6.  Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

Authors:  Amit M Oza; David Cibula; Ana Oaknin Benzaquen; Christopher Poole; Ron H J Mathijssen; Gabe S Sonke; Nicoletta Colombo; Jiří Špaček; Peter Vuylsteke; Holger Hirte; Sven Mahner; Marie Plante; Barbara Schmalfeldt; Helen Mackay; Jacqui Rowbottom; Elizabeth S Lowe; Brian Dougherty; J Carl Barrett; Michael Friedlander
Journal:  Lancet Oncol       Date:  2014-12-04       Impact factor: 41.316

7.  Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.

Authors:  Jee Suk Chang; Sang Wun Kim; Yeon-Joo Kim; Joo-Young Kim; Sang-Yoon Park; Jin Hee Kim; Tae-Kyu Jang; Yong Bae Kim
Journal:  Gynecol Oncol       Date:  2018-08-24       Impact factor: 5.482

8.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

9.  Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study.

Authors:  Nathalie Rochet; Florian Sterzing; Alexandra D Jensen; Julien Dinkel; Klaus K Herfarth; Kai Schubert; Michael H Eichbaum; Andreas Schneeweiss; Christof Sohn; Juergen Debus; Wolfgang Harms
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-21       Impact factor: 7.038

10.  Salvage whole abdomen radiation therapy: its role in ovarian cancer.

Authors:  S Reddy; M S Lee; E Yordan; J Graham; P Sarin; F R Hendrickson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-11-15       Impact factor: 7.038

View more
  1 in total

1.  MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy.

Authors:  Yi Cai; Baiping An; Dejiao Yao; Hong Zhou; Jie Zhu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.